Research programme: genetically modified tumour-infiltrating lymphocytes - PolyBioCept AB/Iovance Biotherapeutics

Drug Profile

Research programme: genetically modified tumour-infiltrating lymphocytes - PolyBioCept AB/Iovance Biotherapeutics

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PolyBioCept
  • Developer Iovance Biotherapeutics; PolyBioCept
  • Class T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
  • 15 Sep 2016 Lion Biotechnologies and Karolinska University Hospital plan two phase I trials for Glioblastoma and Pancreatic cancer in Sweden
  • 15 Sep 2016 Lion Biotechnologies in-licenses tumour-infiltrating lymphocytes technology and patents from PolyBioCep
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top